| Theme | Progress in the management of phosphorus in chronic kidney disease | |
|---|---|---|
| Title | Importance of phosphate control for uremic patients | |
| Publish Date | 2004/10 | |
| Author | Masahide Mizobuchi | Center of Blood Purification Therapy, Wakayama Medical Universitye |
| Author | Maki Ohura | Center of Blood Purification Therapy, Wakayama Medical Universitye |
| Author | Tadao Akizawa | Center of Blood Purification Therapy, Wakayama Medical Universitye |
| [ Summary ] | Calcium (Ca)-phosphate (P) metabolism disorders, caused by uremia, have major affects on the progression of secondary hyperparathyroidism (SHPT). P not only stimulates parathyroid hormone (PTH) secretion but also has been demonstrated to be a risk factor for cardiovascular diseases and mortality of patients with uremic problems. Recently, it has been reported in invitro studies that P has an important role for vascular calcification. Sevelamer is indicated as a potentially useful drug in preventing vascular calcification. Fibroblast growth factor-23 (FGF-23) has been identified as a physiologic factor for the regulation of P and vitamin D metabolism. The investigation of P metabolism has now reached a new stage. Further studies are needed to elucidate detailed P metabolism and to establish accurate tools to control P. | |